• Sanofi SA, of Paris, and the Curie Institute, through its Curie-Cancer partnership under the Institut Carnot label, said they established a three-year research collaboration to identify therapeutic targets for the development of treatments for ovarian cancer. Read More
• ALK-Abello A/S, of Horsholm, Denmark, reported a positive outcome of the first of two pivotal Phase III trials of its allergy immunotherapy tablet for the treatment of house dust mite-induced respiratory diseases, demonstrating that the treatment has a significant clinical effect in allergic rhinitis. Read More
• Neuroderm Ltd., of Ness Ziona, Israel, said results from a Phase I study in volunteers and preliminary data from a Phase IIa study in advanced Parkinson's patients showed that ND0612 was found to be safe and tolerable and maintained steady state, clinically meaningful levodopa plasma concentrations. Read More
• Amarin Corp. plc, of Dublin, Ireland, said the FDA will convene an advisory committee on Oct. 16 in connection with the agency's review of the supplemental new drug application seeking approval for the use of Vascepa (icosapent ethyl) capsules as an adjunct to diet in the treatment of adult patients with high triglycerides. Read More
The potential value of cell therapy in wound care applications grabbed the attention of the biotech world last fall when Smith & Nephew plc, of London, picked up Fort Worth, Texas-based Healthpoint Biotherapeutics for $782 million in cash on the strength of its cell therapy product, HP802-247, in wound care. Read More
By combining Namenda (memantine, Forest Laboratories Inc.) with nitroglycerin, researchers have developed a compound that appears capable of repairing damaged synapses in animal models of Alzheimer's disease. Read More
The longer timelines the FDA is proposing for biosimilar meetings and reviews add insult to the injury of expecting sponsors of the follow-on biologics (FOBs) to pay user fees up front, according to several generic drugmakers. Read More
